Compare D R Horton Inc (DHI) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? D R Horton Inc trades at $135.82 (market cap $37.99B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| DHI | TAK | |
|---|---|---|
Market Cap | $37.99B | $58.74B |
Volume | 2,974,460 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $19.05 |
52-Week Low | $132.53 | $13.23 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $43.09B | $86.65B |
Dividend Yield | 1.33% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) is trading at $133.28, down 2.54% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 12.71 and P/S of 1.16, while maintaining solid profitability with 9.15% net margin. Recent earnings have consistently beaten expectations, though revenue declined to $34.25B in 2025. Technical indicators show oversold conditions with RSI at 26.75, while analyst consensus remains positive with $156.57 price target.
DHI presents a value opportunity with strong fundamentals but faces near-term headwinds from rising mortgage rates and housing market weakness. The 47% upside to consensus target offers potential reward, though investors must weigh housing sector volatility against the company's consistent execution and shareholder returns including dividends and buybacks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
